share_log

Ardelyx | 8-K: Current report

Ardelyx | 8-K: Current report

Ardelyx | 8-K：重大事件
美股sec公告 ·  07/02 07:09
Moomoo AI 已提取核心訊息
On July 2, 2024, Ardelyx, Inc., a biopharmaceutical company, announced its decision not to seek inclusion of its drug XPHOZAH (tenapanor) in the CMS ESRD PPS TDAPA. This decision was made to maintain patient access to XPHOZAH, which is a phosphate absorption inhibitor used in the treatment of patients with end-stage renal disease. The announcement was made in a Form 8-K filing with the SEC. Ardelyx, which is traded on the Nasdaq Global Market under the symbol ARDX, did not provide further details on the implications of this decision or any alternative strategies it might pursue.
On July 2, 2024, Ardelyx, Inc., a biopharmaceutical company, announced its decision not to seek inclusion of its drug XPHOZAH (tenapanor) in the CMS ESRD PPS TDAPA. This decision was made to maintain patient access to XPHOZAH, which is a phosphate absorption inhibitor used in the treatment of patients with end-stage renal disease. The announcement was made in a Form 8-K filing with the SEC. Ardelyx, which is traded on the Nasdaq Global Market under the symbol ARDX, did not provide further details on the implications of this decision or any alternative strategies it might pursue.
2024年7月2日，生物製藥公司Ardelyx宣佈決定不尋求將其藥物XPHOZAH (tenapanor) 納入CMS ESRD PPS TDAPA計劃。 該決定是爲了維護終末期腎臟疾病患者對磷吸收抑制劑XPHOZAH的使用權。該公告在提交給SEC的8-K表單中進行了發佈。Ardelyx在納斯達克全球貨幣市場上交易，代碼爲ARDX，沒有提供有關此決定的影響或任何可能採取的替代策略的進一步細節。
2024年7月2日，生物製藥公司Ardelyx宣佈決定不尋求將其藥物XPHOZAH (tenapanor) 納入CMS ESRD PPS TDAPA計劃。 該決定是爲了維護終末期腎臟疾病患者對磷吸收抑制劑XPHOZAH的使用權。該公告在提交給SEC的8-K表單中進行了發佈。Ardelyx在納斯達克全球貨幣市場上交易，代碼爲ARDX，沒有提供有關此決定的影響或任何可能採取的替代策略的進一步細節。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息